Ascentage Pharma Group International

Price & Volume

Stats

52W Range	$17.55-$48.45
Market Cap	$2.2B
Shares Short	24

Financials

Revenue (12 Mos)	$390.6M
Revenue Growth (YoY)	-71.6%
Gross Profit (12 Mos)	$354.9M
Diluted EPS	-$2.11

News

Yahoo Finance • 24 days ago

Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288

Yahoo Finance • 3 months ago

ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

Yahoo Finance • 3 months ago

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%

Yahoo Finance • 3 months ago

ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP

About

CEO	Dr. Dajun Yang M.D., Ph.D.
Address	Suzhou Industrial Park, Suzhou, China, 215000
Sector	Healthcare
Industry	Biotechnology
Full-Time Employees	605